Overview

Safety and Tolerability Study for Age-Related Macular Degeneration

Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
Phase 1: The purpose of this study is to evaluate the safety and tolerability of single ascending doses of hI-con1™ for subjects with Age-Related Macular Degeneration. Phase 2: The purpose of this study is to evaluate the safety of 3 injections of hI-con1™ at 2 different dose levels.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Iconic Therapeutics, Inc.
Treatments:
Immunoconjugates